Glycemic ControlHybrid closed-loop system

Clinical evidence dossier

Hybrid closed-loop system

Time above range

Evidence signal

Authoritative evidence signal

strong

This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.

Evidence snapshot

Authoritative support records
3
Supporting studies available for review
3
Randomized trials
3
Reported effects
15

Clinical conclusion

Hybrid closed-loop system shows a moderate positive evidence signal for improving Time above range across the studied comparisons.

The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.

Observed effects

Observed study estimates; not a pooled treatment effect.

Change from baseline

Absolute change

61.2 to 61.2 %

1 eligible estimates2–2 weeksObserved median: 61.2 %

Between-group effect

Absolute change

-15.6 to -15.6 %

1 eligible estimates2–2 weeksObserved median: -15.6 %

Between-group effect

Absolute change

-15 to 15 percentage points

2 eligible estimates12–12 weeksObserved median: 0 percentage points

Between-group effect

Mean difference

15.2 to 15.2 %

1 eligible estimates2–2 weeksObserved median: 15.2 %

Evidence composition

Non-randomized studies
0
Other designs
0
Unresolved designs
0
Magnitude-eligible effects
5

Consistency

Authoritative consistency classification

consistent

Positive
3
No effect
0
Mixed
0
Negative
0

Population and applicability

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.

View reported population descriptions

These descriptions are reported across the supporting studies; they are not a single synthesized population.

  • Young Adult (19–39)
  • Middle Aged (40-64)
  • Older Adults (65+)
  • Male
  • Female
  • with T1 Diabetes
  • Adults with type 2 diabetes managing their condition with insulin.
  • Individuals seeking improved glycemic control through advanced therapy options.
  • Adults with Type 2 diabetes undergoing surgery.
  • Patients requiring insulin therapy during the perioperative period.

Limitations

  • Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.
  • 2 of 3 studies with duration data have follow-up of 12 weeks or less.
  • 1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Supporting evidence

Inspect the authoritative studies and omitted support records for this dossier.

View supporting evidence